Boothbay Fund Management’s Epizyme, Inc EPZM Stock Holding History

Boothbay Fund Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25,338	Closed	-$37K	–	2846
2022 Q2	$37K	Buy	+25,338	New	+$18.6K	﹤0.01%	2112
2022 Q1	–	Sell	-13,948	Closed	-$35K	–	2681
2021 Q4	$35K	Buy	+13,948	New	+$54.8K	﹤0.01%	1794
2020 Q4	–	Sell	-10,934	Closed	-$130K	–	1500
2020 Q3	$130K	Buy	+10,934	New	+$146K	0.01%	972
2020 Q1	–	Sell	-25,000	Closed	-$615K	–	1155
2019 Q4	$615K	Buy	+25,000	New	+$371K	0.05%	437
2019 Q3	–	Sell	-47,474	Closed	-$596K	–	956
2019 Q2	$596K	Buy	+47,474	New	+$611K	0.05%	374
2018 Q4	–	Sell	-33,592	Closed	-$356K	–	976
2018 Q3	$356K	Buy	+33,592	New	+$383K	0.04%	459
2017 Q3	–	Sell	-14,882	Closed	-$227K	–	821
2017 Q2	$225K	Buy	+14,882	New	+$225K	0.05%	516

Other funds holding EPZM

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Boothbay Fund Management's EPZM Position: Q3 2022 in Review

Boothbay Fund Management sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 25,338 shares — an estimated $37K sold.

Boothbay Fund Management first reported a position in EPZM in Q2 2017 and held it in 7 quarters. The position peaked at $615K in Q4 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

Boothbay Fund Management reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
Boothbay Fund Management sold 25,338 Epizyme, Inc shares in Q3 2022, an estimated $37K.
Boothbay Fund Management first reported a position in Epizyme, Inc in Q2 2017 and held it in 7 quarters.
Boothbay Fund Management's Epizyme, Inc position peaked at $615K in Q4 2019.
0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.